In one published by Chen and colleagues, sunitinib stabilized tumor growth after two years of treatment but was noted to worsen hypoglycemia, an effect attributed to the drug’s ability to enhance glucose-dependent insulin secretion and reduce insulin clearance [96,97,98]. The gene discussed is INS; the disease is neoplasm.